REFERENCE
Blank PR, Schwenkglenks M, Pestalozzi BC, Moch H, Szucs TD.Cost-effectiveness of predictive markers in breast cancer: an analysis from a Swiss perspective. 45th Annual Meeting of the American Society of Clinical Oncology: 342 abstr. 6578, 30 May 2009. Available from: URL: http://www.abstract.asco.org
Tsoi DT, Inoue M, Kelly CM, Verma S, Pritchard K.Cost-effectiveness analysis of oncotype DX-guided treatment in early breast cancer. 45th Annual Meeting of the American Society of Clinical Oncology: abstr. e11536, 29 May 2009. Available from: URL: http://www.abstract.asco.org
Tong KB, Chen E, Brink G, Bender R, de Snoo F, Malin J.Cost-effectiveness of targeting chemotherapy with the 70-gene prognostic signature in early-stage breast cancer patients. 45th Annual Meeting of the American Society of Clinical Oncology: 340 abstr. 6570, 30 May 2009. Available from: URL: http://www.abstract.asco.org
Mercier C, Brunet C, Yang C, Dupuis C, Bagarry-Liegey D, Duflo S, Giovanni A, Zanaret M, Lacarelle B, Duffaud F, Ciccolini J.Pharmacoeconomic study in head and neck cancer patients: impact of prospective DPD deficiency screening with 5-fluorouracil dose tailoring on toxicities-related costs. 45th Annual Meeting of the American Society of Clinical Oncology: 326 abstr. 6515, 31 May 2009. Available from: URL: http://www.abstract.asco.org
Latimer RG, Presant CA, Hallquist AE, Perree M, Agapitos D.The value of personalized treatment planning: cost savings by the Microculture Kinetic chemosensitivity assay, evidence from a large American self-insured company. 45th Annual Meeting of the American Society of Clinical Oncology: abstr. e17541, 29 May 2009. Available from: URL: http://www.abstract.asco.org
Rights and permissions
About this article
Cite this article
A personal touch - the value of guided treatment in cancer care. Pharmacoecon. Outcomes News 580, 7–8 (2009). https://doi.org/10.2165/00151234-200905800-00016
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200905800-00016